Javascript must be enabled to continue!
Key Research Studies in Clinical Psychopharmacology
View through CrossRef
A number of key clinical research studies in psychopharmacology are presented and critiqued. They include some classic studies dating back decades, to current studies involving the most recent important studies or analyses of clinical research in psychopharmacology—such as diagnostic validators in psychiatry, a maintenance RCT of olanzapine in bipolar illness, brain effects of dopamine blockers, whether antidepressants prevent depression or not, the use of paroxetine in depression, the natural history of treated depression today, adult attention-deficit disorder, and treatment response in first-episode depression. The critiques provided often show that the claimed results of studies are different from the actual data, which need independent interpretation.
Title: Key Research Studies in Clinical Psychopharmacology
Description:
A number of key clinical research studies in psychopharmacology are presented and critiqued.
They include some classic studies dating back decades, to current studies involving the most recent important studies or analyses of clinical research in psychopharmacology—such as diagnostic validators in psychiatry, a maintenance RCT of olanzapine in bipolar illness, brain effects of dopamine blockers, whether antidepressants prevent depression or not, the use of paroxetine in depression, the natural history of treated depression today, adult attention-deficit disorder, and treatment response in first-episode depression.
The critiques provided often show that the claimed results of studies are different from the actual data, which need independent interpretation.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Safety Methodology in Pediatric Psychopharmacology Trials
Safety Methodology in Pediatric Psychopharmacology Trials
In recent years, there has been an increase in pediatric clinical trials as the result of an identified need for greater research with this population. Given the potential risks, a...
Psychopharmacology and social psychiatry
Psychopharmacology and social psychiatry
Abstract
The advent of modern psychopharmacology has shaped modern psychiatry like no other event. For the first time, it became possible to treat severe mental diso...
AI-infused patients for enhanced clinical simulation
AI-infused patients for enhanced clinical simulation
Artificial intelligence (AI) refers to the simulation of human intelligence in computers, allowing them to perform tasks that usually require human cognitive abilities, such as dec...

